| [1] |
SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. |
| [2] |
|
| [3] |
Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of primary liver cancer (2020 edition)[M]. Beijing: People's Medical Publishing House, 2020.
中国临床肿瘤学会指南工作委员会. 原发性肝癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020.
|
| [4] |
EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2. |
| [5] |
FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307. |
| [6] |
QIN S, REN Z, MENG Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470-2045(20)30011-5. |
| [7] |
YAU T, PARK JW, FINN RS, et al. LBA38_PR-CheckMate 459: A randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Ann Oncol, 2019, 30(Suppl 5): v874-v875.
|
| [8] |
KUDO M, IKEDA M, MOTOMURA K, et al. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117[J]. J Clin Oncol, 2020, 38(4_suppl): 513. DOI: 10.1200/JCO.2020.38.4_suppl.513. |
| [9] |
FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745. |
| [10] |
XU J, SHEN J, GU S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571. |
| [11] |
SUN HC, ZHU XD, HUANG C, et al. Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study[J]. J Clin Oncol, 2020, 38(15_suppl): e16610. DOI: 10.1200/JCO.2020.38.15_suppl.e16610. |
| [12] |
KOROKI K, KANOGAWA N, MARUTA S, et al. Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma[J]. Liver Cancer, 2021. [Online ahead of print] DOI: 10.1159/000515552. |
| [13] |
EXPOSITO MJJ, AKCE M, ALVAREZ JLM, et al. 209TiP-CA209-9DX: Phase Ⅲ, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablationp[J]. Ann Oncol, 2018, 29(Suppl 9): ix65.
|
| [14] |
KUDO M, MOTOMURA K, WADA Y, et al. Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: Results from the phase 1b VEGF liver 100 trial[J]. Liver Cancer, 2021, 10(3): 249-259. DOI: 10.1159/000514420. |
| [15] |
PINTER M, JAIN RK, DUDA DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: A review[J]. JAMA Oncol, 2021, 7(1): 113-123. DOI: 10.1001/jamaoncol.2020.3381. |
DownLoad: